President Trump has issued an Executive Order directing the rescheduling of cannabis to Schedule III under the Controlled Substances Act—a significant development with potential implications for cannabis operators, healthcare stakeholders, and other regulated industries.

At Feldman Legal Advisors, we break down what this executive order does (and does not) do, the legal and regulatory context, and what stakeholders should be watching as the process moves forward.